NEW YORK (GenomeWeb News) – SuperNova Diagnostics today said that it will collaborate with Shenzhen Kang Bao Bio-Technology (KSB) on developing and commercializing diagnostics and services for the measurement of the analyte neopterin.
The firms plan to develop the products and services using SuperNova's AmpCrystal technology and offer them in China and affiliated markets. Financial and further details of the collaboration were not disclosed.
The AmpCrystal technology is based on liquid crystal display and uses hyper-dense, energy-mediated nanocrystals in an effort to overcome the limitations inherent in current molecular and immunoassay technologies.
According to SuperNova, neopterin is an analyte that is gaining interest for use in detecting and monitoring, as well as the prognosis of, acute and chronic inflammatory responses. The marker may be implicated in more than 80 inflammation-mediated diseases including cardiovascular, CNS, infectious diseases, and others.
"This collaborative agreement allows SuperNova and KSB to expand R&D, manufacturing, and commercialization of a proprietary set of biomarkers for acute and chronic inflammatory conditions into one of the world's largest markets initially and then potentially the rest of the world," SuperNova Diagnostics President and CEO Neil Campbell said in a statement.
SuperNova and KSB had announced two weeks ago that they would collaborate but didn't offer any details at that time.